Nucl Med Mol Imaging.  2021 Jun;55(3):130-135. 10.1007/s13139-021-00695-6.

Extended Whole‑body Ga‑68 DOTATATE PET‑CT in evaluating Tumour‑Induced Osteomalacia: Case report and review of literature

• Tan T
• Chen E
• Chew M
• Chye P
• Wong M

• KMID: 2516691
• DOI: http://doi.org/10.1007/s13139-021-00695-6

Abstract

Tumour-induced osteomalacia is a rare paraneoplastic syndrome that manifests as chronic hypophosphataemia, non-specific bone pain and muscle weakness. It is generally caused by phosphaturic mesenchymal tumour (PMT), which is uncommonly associated with synchronous tumours. However, diagnosis is often delayed for several years due to the rarity, indolent growing nature and non-specific symptoms of the disease, often resulting in an overlook by clinicians during assessments. The patient initially presented with hypophosphataemia and generalised skeletal pain with multiple atraumatic fractures. Blood tests revealed serum calcium levels at the upper limit and extremely low inorganic phosphate levels. Herein, we report a case where two synchronous PMTs from two different sites were detected by ‘extended’ whole-body Ga-68 DOTATATE PET-CT, leading to remission of the disease after complete surgical removal. Early detection and diagnosis of PMT neoplasm is crucial, as complete surgical resection of this tumour is the only definitive treatment currently known. Upon excision, this curable disease will result in complete resolution of symptoms and blood parameters, leading to remission of the disease which significantly improves the patient’s quality of life. PMT often over-expresses somatostatin receptors (SSTR), predominantly subtype 2A, and Ga-68 DOTATATE PET-CT is a selective SSTR imaging that targets this characteristic over-expression in these tumours. The high diagnostic accuracy of Ga-68 DOTATATE PET-CT should be the primary imaging modality for full evaluation of this disease.

Keyword

Tumour-induced osteomalacia; Phosphaturic mesenchymal tumour; Ga-68 DOTATATE PET-CT; Hypophosphataemia